European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European UnionBusiness Wire • 08/24/26
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's DataMarketBeat • 08/12/26
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 08/07/26
3 Medical Stocks Standing Out After Crushing Q2 Earnings ExpectationsZacks Investment Research • 08/06/26
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product SalesZacks Investment Research • 08/05/26
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/04/26
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth ConferenceBusiness Wire • 07/30/26
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/28/26
Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to TradeZacks Investment Research • 07/23/26
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease CandidateZacks Investment Research • 07/21/26
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease PsychosisBusiness Wire • 07/20/26
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026Business Wire • 07/15/26
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?The Motley Fool • 07/11/26
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett SyndromeZacks Investment Research • 06/29/26